

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Product datasheet for TL509192V

Spata2 Mouse shRNA Lentiviral Particle (Locus ID 263876)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	Spata2 Mouse shRNA Lentiviral Particle (Locus ID 263876)
Locus ID:	263876
Synonyms:	AI504642; mKIAA0757
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	Spata2 - Mouse shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
RefSeq:	<u>BC034597, NM 170756, NM 001356523, NM 170756.1, NM 170756.2</u>
UniProt ID:	<u>Q8K004</u>
Summary:	Bridging factor that mediates the recruitment of CYLD to the LUBAC complex, thereby regulating TNF-alpha-induced necroptosis (By similarity). Acts as a direct binding intermediate that bridges RNF31/HOIP, the catalytic subunit of the LUBAC complex, and the deubiquitinase (CYLD), thereby recruiting CYLD to the TNF-R1 signaling complex (TNF-RSC) (By similarity). Required to activate the 'Met-1'- (linear) and 'Lys-63'-linked deubiquitinase activities of CYLD (PubMed:28701375). Controls the kinase activity of RIPK1 and TNF-alpha-induced necroptosis by promoting 'Met-1'-linked deubiquitination of RIPK1 by CYLD (PubMed:28701375). [UniProtKB/Swiss-Prot Function]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u> . If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u> .



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2022 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US

GRIGENE Spata2 Mouse shRNA Lentiviral Particle (Locus ID 263876) – TL509192V

Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2022 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US